Navigation Links
Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Date:5/7/2009

Safety and Efficacy Data from Phase 3 Study will be Highlighted

SAN DIEGO, May 7 /PRNewswire-USNewswire/ -- Chronic pain is a significant medical challenge in the United States, and chronic low back pain is the most common cause of disability in developed countries. An estimated 100 million Americans suffer from chronic pain each year. If left undertreated, chronic pain can impair an individual's ability to carry out daily activities and diminish quality of life.

Three clinical presentations about the use of tapentadol extended release tablets to treat patients with chronic low back pain, including pivotal Phase 3 safety, efficacy and gastrointestinal tolerability data, will be discussed during the poster sessions of the 28th Annual Scientific Meeting of the American Pain Society (APS) in San Diego, California on Thursday, May 7, and Friday, May 8, 2009. These data presentations are supported by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD).

Tapentadol binds to mu-opioid receptors and inhibits norepinephrine re-uptake. Although the exact mechanism of action is not known, these two mechanisms, which affect established pain pathways, are thought to be responsible for pain relief with tapentadol. The U.S. Drug Enforcement Agency has proposed placing the tapentadol molecule into Schedule II of the Controlled Substances Act.

J&JPRD continues to study tapentadol extended release formulation for chronic pain, and a New Drug Application (NDA) is planned for submission to the United States Food and Drug Administration (FDA) this year. The NDA filing is part of the ongoing commitment of J&JPRD and PriCara(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to bring new and innovative products to patients and physicians for the treatment and management of pain.

The following posters on tapentadol extended release data will
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
2. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
5. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
6. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
7. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
8. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
9. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
10. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...DGE, N.J., Nov. 25 Regado Bioscien...ent of antithrombotic aptamers with active control...President, will be presenting at the Piper Jaffray...k Palace Hotel in New York City. Dr. Mazzo,s pres... December 1 and will include an overview of the Co...
(Date:11/25/2009)...ORK, Nov. 25 Reportlinker.com anno...le in its catalogue: ,, Mammography Equipment....reportlinker.com/p0164330/Mammography-Equipment--...cidence of breast cancer in industrialized as well...encing growth in the mammography market. Globally,...
(Date:11/25/2009)...AM, Mass., Nov. 25 According to Mi...y on medical technology market intelligence, the n...ices will continue to see rapid growth over the ne.... MRG,s US Markets for Trauma Devices 2010 rep...mic over the next five years, with competitors int...
Breaking Medicine Technology:Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3This Summer is an Ideal Time for Commercial Real Estate Lease Renewal 53022 1This Summer is an Ideal Time for Commercial Real Estate Lease Renewal 53022 2This Summer is an Ideal Time for Commercial Real Estate Lease Renewal 53022 3PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach 53020 1PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach 53020 2SAFC Biosciences 28R 29 Defines Hydrolysate Components That Enhance Chinese Hamster Ovary 28CHO 29 Cell Line Protein Production 13241 1SAFC Biosciences 28R 29 Defines Hydrolysate Components That Enhance Chinese Hamster Ovary 28CHO 29 Cell Line Protein Production 13241 2SAFC Biosciences 28R 29 Defines Hydrolysate Components That Enhance Chinese Hamster Ovary 28CHO 29 Cell Line Protein Production 13241 3SAFC Biosciences 28R 29 Defines Hydrolysate Components That Enhance Chinese Hamster Ovary 28CHO 29 Cell Line Protein Production 13241 4
...IOPHARM Oncology,Inc. (NASDAQ: ZIOP), announced t...nnual International Myeloma Workshop being,held in...highlights,important advances made in the biology ...senting darinaparsin (ZIO-101) gene,expression pro...hanism of action as well as interim Phase II data ...
...CADE, lenalidomide,and dexamethasone , ,KOS, Greec...armaceuticals, Inc. (Nasdaq: MLNM) today reported ...trials of VELCADE based,therapies that showed cons...mplete response(1) (CR) rates in newly diagnosed,m...sented at the,prestigious 11th International Myelo...
Other Medicine Technology:ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 2ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 3ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
(Date:11/27/2009)...Nov.27/PRNewswire-USNewswire/--Consideredahighlyri...solidorgantransplantationisnowalife-savingmainstre...atheredattheWinspearOperaHouseinDallasonNov.11.Lea...celebratethe25thanniversaryofBaylorRegionalTranspl...nsplantintheUnitedStates. ,, Itwas25yearsagotha...
(Date:11/27/2009)... XenaCare Holdings has announced that it...undation, one of the largest nonprofit organizatio...th education. , Delray Be...ings, Inc. (OTCBB: XCHO), a company specializing i...r healthcare products, has announced today that is...
(Date:11/27/2009)... Multi-purpose bilingual coloring books ...se by the business community to educate - inform p... from Safety issues to Dinosuars to ABC,S and a ho...nt Louis, MO (PRWEB) November 27, 2009 -- Today&rs... toys to keep them busy any hour of the day, but o...
(Date:11/26/2009)...5 years, the number of Americans living with diabe...on in 2009 to 44.1 million in 2034. Over the same ...ising from $113 billion to $336 billion, even with...hers based at the University of Chicago report in ...ber of those with diabetes covered by Medicare wil...
(Date:11/26/2009)... Dr. David Kim of the Live Life Again Ce...Dallas , is one of a growing number of physicians ...king sites to connect with individuals who are int... morbid obesity. Dr. Kim is utilizing Facebook to ...t his practice with the community. , ...
Breaking Medicine News(10 mins):Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3
...IS, July 1 Uroplasty, Inc. (Amex:,UPI), a medical...rkets,innovative proprietary products for the trea... it was added to the Russell Microcap(R) Index whe... which remains in place for one,year, means automa...
...LIS, July 1 CoLucid Pharmaceuticals, Inc., an,inn...s for central nervous,system disorders, announced ...vestor Care Capital led the round, which included ...r develop a,unique migraine compound, COL-144, and...
... New research shows that a majori... pay higher taxes to fund increased education faci...d consumer attitudes to the recruitment of nurses ...are survey are concerned about the on-going effect...
...ELPHIA In the first study of its kind, researcher...Medicine,s Ross Koppel, Ph.D. studied how hospital...ches the right patient with the right dose of the ...tion administration errors, is flawed, and can inc...
...follow-up to research showing that psilocybin, a s... substantial spiritual effects, a Johns Hopkins te... last more than a year. , Writing in the Journa... Hopkins study published in 2006, continued to say...
...E, N.J., June 30 Janssen, Division,of Ortho-McNei... has,launched an authorized generic version of RIS...icals, L.L.C., Patriot is a subsidiary of McNeil-...RISPERDAL, which was first approved by the FDA in ...
Other Medicine News:Health News:Uroplasty Joins the Russell Microcap Index 2Health News:Uroplasty Joins the Russell Microcap Index 3Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 2Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 3Health News:CoLucid Pharmaceuticals Announces $25 Million Series B Financing for Advancement of First-in-Class Migraine Compound 4Health News:Education More Important Than Immigration to Solve Nursing Shortage, Research Shows 2Health News:Education More Important Than Immigration to Solve Nursing Shortage, Research Shows 3Health News:Flaws in the barcoded technology used to reduce medication administration errors identified 2Health News:Flaws in the barcoded technology used to reduce medication administration errors identified 3Health News:Flaws in the barcoded technology used to reduce medication administration errors identified 4Health News:Spiritual effects of hallucinogens persist, Johns Hopkins researchers report 2Health News:Janssen Announces Launch of Authorized Generic for RISPERDAL(R) 2Health News:Janssen Announces Launch of Authorized Generic for RISPERDAL(R) 3Health News:Janssen Announces Launch of Authorized Generic for RISPERDAL(R) 4
Sealing Mat for 384-well PCR plate
...pha unit, these new pads may be used in applicatio...essive runs may be sealed with the same pad. The M...te from sticking to the block and lid, and Microse...rformance, which means you can use as little as 50...
...pha unit, these new pads may be used in applicatio...essive runs may be sealed with the same pad. The...late from sticking to the block and lid, and Micro...performance, which means you can use as little as ...
Microseal 'M' mats
Medicine Products: